Sep 5, 2019 Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Sep 4, 2019 Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones
Aug 16, 2019 Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants
Aug 14, 2019 CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
Aug 14, 2019 Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
Aug 13, 2019 Oncolytics Biotech(R) Reports 2019 Second Quarter Financial Results and Operational Highlights
Jul 23, 2019 Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)
Jun 5, 2019 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
